DR. DATSONS LABS | PIRAMAL ENTERPRISES | DR. DATSONS LABS/ PIRAMAL ENTERPRISES |
|||
---|---|---|---|---|---|
P/E (TTM) | x | -10.9 | -48.7 | - | View Chart |
P/BV | x | 0.2 | 1.6 | 9.9% | View Chart |
Dividend Yield | % | 0.0 | 1.4 | - |
![]() ![]() |
EQUITY SHARE DATA | |||||
---|---|---|---|---|---|
DR. DATSONS LABS Mar-14 |
PIRAMAL ENTERPRISES Mar-19 |
DR. DATSONS LABS/ PIRAMAL ENTERPRISES |
5-Yr Chart Click to enlarge
|
||
High | Rs | 126 | 3,303 | 3.8% | |
Low | Rs | 31 | 1,797 | 1.7% | |
Sales per share (Unadj.) | Rs | 133.0 | 716.5 | 18.6% | |
Earnings per share (Unadj.) | Rs | 0.2 | 79.7 | 0.2% | |
Cash flow per share (Unadj.) | Rs | 6.6 | 107.9 | 6.1% | |
Dividends per share (Unadj.) | Rs | 0 | 28.00 | 0.0% | |
Dividend yield (eoy) | % | 0 | 1.1 | 0.0% | |
Book value per share (Unadj.) | Rs | 128.8 | 1,477.5 | 8.7% | |
Shares outstanding (eoy) | m | 31.66 | 184.45 | 17.2% | |
Bonus/Rights/Conversions | FCCB | IS | - | ||
Price / Sales ratio | x | 0.6 | 3.6 | 16.5% | |
Avg P/E ratio | x | 516.1 | 32.0 | 1,613.4% | |
P/CF ratio (eoy) | x | 11.8 | 23.6 | 50.1% | |
Price / Book Value ratio | x | 0.6 | 1.7 | 35.2% | |
Dividend payout | % | 0 | 35.1 | 0.0% | |
Avg Mkt Cap | Rs m | 2,477 | 470,292 | 0.5% | |
No. of employees | `000 | NA | 7.8 | 0.0% | |
Total wages/salary | Rs m | 56 | 22,504 | 0.2% | |
Avg. sales/employee | Rs Th | NM | 16,899.4 | - | |
Avg. wages/employee | Rs Th | NM | 2,877.7 | - | |
Avg. net profit/employee | Rs Th | NM | 1,879.9 | - |
INCOME DATA | |||||
---|---|---|---|---|---|
Net Sales | Rs m | 4,211 | 132,153 | 3.2% | |
Other income | Rs m | 79 | 3,128 | 2.5% | |
Total revenues | Rs m | 4,289 | 135,281 | 3.2% | |
Gross profit | Rs m | 569 | 66,290 | 0.9% | |
Depreciation | Rs m | 204 | 5,202 | 3.9% | |
Interest | Rs m | 430 | 44,097 | 1.0% | |
Profit before tax | Rs m | 13 | 20,119 | 0.1% | |
Minority Interest | Rs m | 0 | 3,194 | 0.0% | |
Prior Period Items | Rs m | -2 | 0 | - | |
Extraordinary Inc (Exp) | Rs m | 0 | 0 | - | |
Tax | Rs m | 6 | 8,611 | 0.1% | |
Profit after tax | Rs m | 5 | 14,701 | 0.0% | |
Gross profit margin | % | 13.5 | 50.2 | 26.9% | |
Effective tax rate | % | 48.0 | 42.8 | 112.2% | |
Net profit margin | % | 0.1 | 11.1 | 1.0% |
BALANCE SHEET DATA | |||||
---|---|---|---|---|---|
Current assets | Rs m | 6,852 | 122,742 | 5.6% | |
Current liabilities | Rs m | 6,711 | 310,810 | 2.2% | |
Net working cap to sales | % | 3.3 | -142.3 | -2.4% | |
Current ratio | x | 1.0 | 0.4 | 258.5% | |
Inventory Days | Days | 161 | 23 | 697.3% | |
Debtors Days | Days | 318 | 39 | 820.0% | |
Net fixed assets | Rs m | 3,673 | 116,904 | 3.1% | |
Share capital | Rs m | 317 | 369 | 85.8% | |
"Free" reserves | Rs m | 3,761 | 272,161 | 1.4% | |
Net worth | Rs m | 4,078 | 272,530 | 1.5% | |
Long term debt | Rs m | 1,671 | 270,196 | 0.6% | |
Total assets | Rs m | 12,633 | 856,261 | 1.5% | |
Interest coverage | x | 1.0 | 1.5 | 70.7% | |
Debt to equity ratio | x | 0.4 | 1.0 | 41.3% | |
Sales to assets ratio | x | 0.3 | 0.2 | 216.0% | |
Return on assets | % | 3.4 | 6.9 | 50.1% | |
Return on equity | % | 0.1 | 5.4 | 2.2% | |
Return on capital | % | 7.7 | 12.4 | 61.8% | |
Exports to sales | % | 22.9 | 0 | - | |
Imports to sales | % | 14.3 | 0 | - | |
Exports (fob) | Rs m | 964 | NA | - | |
Imports (cif) | Rs m | 602 | NA | - | |
Fx inflow | Rs m | 964 | 15,200 | 6.3% | |
Fx outflow | Rs m | 607 | 4,889 | 12.4% | |
Net fx | Rs m | 357 | 10,312 | 3.5% |
CASH FLOW | |||||
---|---|---|---|---|---|
From Operations | Rs m | 1,345 | -115,975 | -1.2% | |
From Investments | Rs m | -2,256 | -8,265 | 27.3% | |
From Financial Activity | Rs m | -1,200 | 107,525 | -1.1% | |
Net Cashflow | Rs m | -2,111 | -16,650 | 12.7% |
Indian Promoters | % | 4.5 | 52.9 | 8.6% | |
Foreign collaborators | % | 0.0 | 0.0 | - | |
Indian inst/Mut Fund | % | 0.0 | 4.0 | - | |
FIIs | % | 1.4 | 26.6 | 5.1% | |
ADR/GDR | % | 0.0 | 0.0 | - | |
Free float | % | 94.1 | 16.5 | 570.3% | |
Shareholders | 20,807 | 93,274 | 22.3% | ||
Pledged promoter(s) holding | % | 0.0 | 0.0 | - |
Compare DR. DATSONS LABS With: CADILA HEALTHCARE TTK HEALTHCARE NEULAND LABS BIOCON J.B.CHEMICALS
Compare DR. DATSONS LABS With: ACTAVIS (US) MYLAN (US) ADCOCK INGRAM (S. Africa) TEVA PHARMA (Israel)
Asian share markets edged higher today as investors shrugged off concerns that stocks may have rallied too far too fast in the past year.
PIRAMAL ENTERPRISES share price has hit a 52-week high. It is presently trading at Rs 1,969. BSE 500 Index is up by 0.9% at 20,109. Within the BSE 500, PIRAMAL ENTERPRISES (up 2.6%) and IFCI (up 11.8%) are among the top gainers, while top losers are IRCON INTERNATIONAL and MMTC.
For the quarter ended June 2020, PIRAMAL ENTERPRISES has posted a net profit of Rs 5 bn (up 22.1% YoY). Sales on the other hand came in at Rs 29 bn (down 16.2% YoY). Read on for a complete analysis of PIRAMAL ENTERPRISES's quarterly results.
For the quarter ended December 2019, PIRAMAL ENTERPRISES has posted a net profit of Rs 6 bn (up 11.7% YoY). Sales on the other hand came in at Rs 38 bn (up 9.1% YoY). Read on for a complete analysis of PIRAMAL ENTERPRISES's quarterly results.
For the quarter ended September 2019, PIRAMAL ENTERPRISES has posted a net profit of Rs 6 bn (up 16.5% YoY). Sales on the other hand came in at Rs 36 bn (up 14.6% YoY). Read on for a complete analysis of PIRAMAL ENTERPRISES's quarterly results.
For the quarter ended June 2019, PIRAMAL ENTERPRISES has posted a net profit of Rs 4 bn (up 390.0% YoY). Sales on the other hand came in at Rs 35 bn (up 20.8% YoY). Read on for a complete analysis of PIRAMAL ENTERPRISES's quarterly results.
More Views on NewsLast time the smallcap index crossed 19k a big correction followed. Here's what makes it different this time.
In this video, I'll show you how to get started on the path to daily trading profits.
In this episode, ace trader Brijesh Bhatia talks to us about the best investments of 2021, his profitable trading system, and much more.
An Indian company founded three decades ago in a garage caught my attention...
More